Xi Portal

ActionMS Home  | Text Only 


You are here: Icon Tabs > Latest Research
Decrease Font Size Increase Font Size
print Print


Search:   Go


Page 1 of 1   
Data
Click here to read: MediKol Brief MediKol Brief
A look at some of the oral drugs in clinical development for MS ...   Read More.....
Click here to read: MediKol Brief MediKol Brief
Low Dose Naltrexone (LDN) for MS ...   Read More.....
Click here to read: Do you have problems with mobility and balance related to MS Do you have problems with mobility and balance related to MS
Researchers at the University of Ulster are carrying out a project to evaluate the effect of group exercise therapy on mobility and balance problems experienced by people with Multiple Sclerosis ...   Read More.....
Click here to read: Multiple Sclerosis patients have significant and sustained reduction in disability and risk of relapse on Alemtuzumab versus Rebif®. Multiple Sclerosis patients have significant and sustained reduction in disability and risk of relapse on Alemtuzumab versus Rebif®.
Edinburgh; UK 23rd October 2008 – Results recently published in the 23rd October issue of the New England Journal of Medicine (N Engl J Med 2008;359:1786-1801) showed very promising results from a cli ...   Read More.....
Page:1


Terms & Conditions  |  ©ActionMS 2017  |  Developed by Adream Solutions Ltd  |  SiteMap

Contact Us  |  Accessibility  |  Directory